DFDA

Surgical Resection

Treatment for Liver Cancer Due To Hepatitis B

Typical Dosage: procedure-based

Effectiveness
90%
Safety Score
25%
Clinical Trials
50
Participants
7K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
procedure-based
Time to Effect
immediate (tumor removal)
Treatment Duration
single surgery, then surveillance
Evidence Quality
HIGH
Confidence Score
85%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$0
Monitoring:$7,000
Side Effect Mgmt:$1,000
Total Annual:$8,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$80,000/QALY
QALYs Gained
4
Comparison vs RFA
Cost Difference
+$30,000/year
More expensive
QALY Difference
-0.20 QALYs
Worse outcomes
Dominance
No dominance
Surgical Resection Outcomes

for Liver Cancer Due To Hepatitis B

Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+100%
Remission Rate
+100%
Common Side Effects
Surgical complications (bleeding, infection)
+15%
Liver failure (in cirrhotic patients)
+10%
Ascites
+20%
Pleural effusion
+10%

Sources:

ctfassets.net
nih.gov
nih.gov

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
No active trials currently recruiting for this treatment

No active trials found in ClinicalTrials.gov